en · de · es · pt
aod-9604-notes.peptides6608.com › Blog › Identity And Research Context — Beginner to Advanced

Identity And Research Context — Beginner to Advanced

By Editorial Desk · published 2026-01-10 · last reviewed 2026-01-26 · Blog

human growth hormone is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-01-26. Numbers and descriptions here follow the published literature rather than marketing material.

Identity and Research Context

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Background and Development History

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Aod-9604 at a glance

PropertyValueNotes
Common nameAOD-9604Development code used in scientific literature.
Chemical classSynthetic peptideFragment of human growth hormone.
Amino acid length16 residuesMatches hGH region 176-191.
AppearanceWhite to off-white powderTypical lyophilized peptide solid.
SolubilitySoluble in waterDissolves in aqueous media; exact behavior depends on salt form.

Reference notes

Among the specimens studied was a previously undescribed specimen of Sinosauropteryx, IVPP V14202, though this specimen is now the holotype of a separate genus Huadanosaurus. By examining melanosome structure and distribution, Zhang and colleagues were able to confirm the presence of light and dark bands of colour in the tail feathers of this specimen (now the holotype of Huadanosaurus) like that of a red panda. Furthermore, the team was able to compare melanosome types to those of modern birds to determine a general range of colour. From the presence of phaeomelanosomes, spherical melanosomes that make and store red pigment, they concluded that the darker feathers of this specimen were chestnut or reddish brown in colour. More research on the coloration of Sinosauropteryx based on three specimens (NIGP 127586, NIGP 127587, and IVPP V12415) reveals that it had a raccoon-like bandit mask and countershading patterns most likely associated with an open habitat, indicating that the Jehol likely had a range of habitat types.

In 2007, she appeared opposite Milla Jovovich in Resident Evil: Extinction, portraying Claire Redfield, who in the film, is the leader of a convoy of zombie apocalypse survivors going to Alaska in search of a safe haven. Her role sent her to Mexicali, Mexico for filming from May to late July, and required her hair to be dyed a light red. Speaking about her character Claire, Larter said, "She became the leader of this convoy. She's incredibly strong, patient. I think she serves a role for everyone within this convoy, let it be a mother to someone, a buddy, a best friend." Despite negative reviews, the film made $147 million worldwide. Also in the same year, she appeared with Hayes MacArthur in the comedy Homo Erectus and appeared as Evelyn Garland in the biographical drama Crazy, based on guitarist Hank Garland. Larter starred opposite Beyoncé and Idris Elba from London, in the Screen Gems-produced thriller Obsessed (2009). The film follows an office executive Derek Charles (Elba) whose marriage to Knowles' character Sharon is threatened by the aggressive interests of a co-worker Lisa Sheridan, portrayed by Larter. In an interview with Glam, Larter said that she "was excited to get the chance to play a femme fatale. I love playing women that are dark and vulnerable and sort of filled with a little bit of crazy emotion." While the film was released to mixed reviews, Larter was critically praised for her performance.

== Influences and style == He described himself as a very inquisitive child saying "I enjoyed catching and keeping living things, such as fish or birds. Other than that, I liked both watching and making animation. Basically, I seemed to be interested in things that moved." Among his favorite subjects in school was art. He commented, "If I was not in the games industry, I would want to become a classical artist. Though I regard not only games but also anything that expresses something – be it films, novels or manga – as forms of art." Ueda played many Sega Mega Drive games, which influenced his work. He was also a fan of the Amiga computer platform games Flashback and Another World during his teen years. Other games that influenced his work include The Legend of Zelda, Virtua Fighter, and Prince of Persia. He was also influenced by the work of Kenji Eno, and the manga series Galaxy Express 999 (1977–1981). Ueda's games are considered to have a distinctive style, which Ueda himself describes as "design by subtraction", with sparse landscapes, oversaturated lighting and minimalist story to give his games a personal and distinctive feel. Ueda also said that, in video games, ideas for a gameplay mechanic should be made first, then complemented by a game's story.

=== Prey === Rattlesnakes typically consume mice, rats, rabbits, ground squirrels, gophers, prairie dogs, ground-nesting birds and other small animals (such as lizards, frogs, toads and occasionally American mink and weasels). They lie in wait for their prey, or hunt for it in holes. The rattlesnake's defence and hunting mechanisms are bound to its physiology and its environment. More importantly environmental temperature can influence the ability of ectotherms. The prey is killed quickly with a venomous bite as opposed to constriction. If the bitten prey moves away before dying, the rattlesnake can follow it by its scent. When it locates the fallen prey, it checks for signs of life by prodding with its snout, flicking its tongue, and using its sense of smell. Once the prey has become incapacitated, the rattlesnake locates its head by odors emitted from the mouth. The prey is then ingested head first, which allows wings and limbs to fold at the joints in a manner that minimizes the girth of the meal. The gastric fluids of rattlesnakes are extremely powerful, allowing for the digestion of flesh and bone. Optimal digestion occurs when the snake maintains a body temperature between 80 and 85 °F (27 and 29 °C). If the prey is small, the rattlesnake often continues hunting. If the meal was adequate, the snake finds a warm, safe location in which to coil up and rest until the prey is digested. Feeding habits play an important ecological role by limiting the size of rodent populations, which prevents crop damage and stabilizes ecosystems.

Sources: en.wikipedia.org

Related pages on this site

Reference notes

On a specific kind of patient At varying dosages For a new indication Evaluation for improved efficacy in treating a condition as compared to the standard therapy for that condition Evaluation of the study drug or device relative to two or more already approved/common interventions for that condition While most clinical trials test one alternative to the novel intervention, some expand to three or four and may include a placebo. Except for small, single-location trials, the design and objectives are specified in a document called a clinical trial protocol. The protocol is the trial's "operating manual" and ensures all researchers perform the trial in the same way on similar subjects and that the data is comparable across all subjects. In 2025 the SPIRIT group released 'SPIRIT 2025', an updated guideline for trial protocols that provides a 34-item minimum checklist, adds a new open-science section, strengthens guidance on reporting harms and intervention/comparator descriptions, and includes a new item on patient and public involvement As a trial is designed to test hypotheses and rigorously monitor and assess outcomes, it can be seen as an application of the scientific method, specifically the experimental step. The most common clinical trials evaluate new pharmaceutical products, medical devices, biologics, diagnostic assays, psychological therapies, or other interventions. Clinical trials may be required before a national regulatory authority approves marketing of the innovation.

== Discovery == The parent structure of lefetamine, 1,2-diphenylethylamine was first synthesized in the 1940s and showed weak analgesic activity. Lefetamine itself was first investigated in Japan in the 1950s. The L-isomer showed weak analgesic action comparable to codeine and antitussive action far weaker than codeine. The d-isomer showed no such activity but caused seizures in rats.

=== COVID-19 therapy === In a phase III study on the treatment of severe courses of COVID-19, sabizabulin reduced mortality by 55% according to the manufacturer. Because of the high efficacy, the test phase was stopped prematurely so that the drug no longer had to be withheld from the placebo control group.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.

Is AOD-9604 the same as human growth hormone?

No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.

Why is it called hGH fragment 176-191?

The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.

What is AOD9604 derived from?

AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.

Network